FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990592740> ?p ?o ?g. }

• W2990592740 endingPage "438" @default.
• W2990592740 startingPage "427" @default.
• W2990592740 abstract "Abstract Background Antidepressants are commonly prescribed for depression, but it is unclear whether treatment efficacy depends on severity and duration of symptoms and how prescribing might be targeted cost-effectively. Objectives We investigated the cost-effectiveness of the antidepressant sertraline compared with placebo in subgroups defined by severity and duration of depressive symptoms. Methods We undertook a cost-effectiveness analysis from the perspective of the NHS and Personal and Social Services (PSS) in the UK alongside the PANDA (What are the indications for Prescribing ANtiDepressants that will leAd to a clinical benefit?) randomised controlled trial (RCT), which compared sertraline with placebo over a 12-week period. Quality of life data were collected at baseline and at 2, 6, and 12 weeks post-randomisation using EQ-5D-5L, from which we calculated quality-adjusted life years (QALYs). Costs (in 2017/18£) were collected using patient records and from resource use questionnaires administered at each follow-up interval. Differences in mean costs and mean QALYs and net monetary benefits were estimated. Our primary analysis used net monetary benefit regressions to identify any interaction between the cost-effectiveness of sertraline and subgroups defined by baseline symptom severity (0–11; 12–19; 20+ on the Clinical Interview Schedule—Revised) and, separately, duration of symptoms (greater or less than 2 years duration). A secondary analysis estimated the cost-effectiveness of sertraline versus placebo, irrespective of duration or severity. Results There was no evidence of an association between the baseline severity of depressive symptoms and the cost-effectiveness of sertraline. Compared to patients with low symptom severity, the expected net benefits in patients with moderate symptoms were £24 (95% CI − £280 to £328; p value 0.876) and the expected net benefits in patients with high symptom severity were £37 (95% CI − £221 to £296; p value 0.776). Patients who had a longer history of depressive symptoms at baseline had lower expected net benefits from sertraline than those with a shorter history; however, the difference was uncertain (− £27 [95% CI − £258 to £204]; p value 0.817). In the secondary analysis, patients treated with sertraline had higher expected net benefits (£122 [95% CI £18 to £226]; p value 0.101) than those in the placebo group. Sertraline had a high probability (> 95%) of being cost-effective if the health system was willing to pay at least £20,000 per QALY gained. Conclusions We found insufficient evidence of a prespecified threshold based on severity or symptom duration that GPs could use to target prescribing to a subgroup of patients where sertraline is most cost-effective. Sertraline is probably a cost-effective treatment for depressive symptoms in UK primary care. Trial Registration Controlled Trials ISRCTN Registry, ISRCTN84544741." @default.
• W2990592740 created "2019-12-05" @default.
• W2990592740 creator A5043141680 @default.
• W2990592740 creator A5052188317 @default.
• W2990592740 creator A5054449436 @default.
• W2990592740 creator A5069618968 @default.
• W2990592740 creator A5070136704 @default.
• W2990592740 creator A5071628619 @default.
• W2990592740 creator A5072246651 @default.
• W2990592740 creator A5078660144 @default.
• W2990592740 creator A5083791593 @default.
• W2990592740 creator A5089632060 @default.
• W2990592740 date "2019-11-27" @default.
• W2990592740 modified "2023-09-26" @default.
• W2990592740 title "Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT" @default.
• W2990592740 cites W1870888192 @default.
• W2990592740 cites W1982564323 @default.
• W2990592740 cites W1990166011 @default.
• W2990592740 cites W1992703315 @default.
• W2990592740 cites W1995713863 @default.
• W2990592740 cites W2013564592 @default.
• W2990592740 cites W2022658070 @default.
• W2990592740 cites W2065974896 @default.
• W2990592740 cites W2080250864 @default.
• W2990592740 cites W2087137161 @default.
• W2990592740 cites W2094608167 @default.
• W2990592740 cites W2102151931 @default.
• W2990592740 cites W2118249259 @default.
• W2990592740 cites W2120590819 @default.
• W2990592740 cites W2120609469 @default.
• W2990592740 cites W2129564365 @default.
• W2990592740 cites W2134843796 @default.
• W2990592740 cites W2139814250 @default.
• W2990592740 cites W2143025931 @default.
• W2990592740 cites W2145618858 @default.
• W2990592740 cites W2150106013 @default.
• W2990592740 cites W2151182129 @default.
• W2990592740 cites W2153403353 @default.
• W2990592740 cites W2153621599 @default.
• W2990592740 cites W2164816593 @default.
• W2990592740 cites W2170351571 @default.
• W2990592740 cites W2402566006 @default.
• W2990592740 cites W2491881490 @default.
• W2990592740 cites W2621832144 @default.
• W2990592740 cites W2765822240 @default.
• W2990592740 cites W2788337440 @default.
• W2990592740 cites W2795956833 @default.
• W2990592740 cites W2974841401 @default.
• W2990592740 doi "https://doi.org/10.1007/s41669-019-00188-5" @default.
• W2990592740 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7426336" @default.
• W2990592740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31777008" @default.
• W2990592740 hasPublicationYear "2019" @default.
• W2990592740 type Work @default.
• W2990592740 sameAs 2990592740 @default.
• W2990592740 citedByCount "3" @default.
• W2990592740 countsByYear W29905927402019 @default.
• W2990592740 countsByYear W29905927402023 @default.
• W2990592740 crossrefType "journal-article" @default.
• W2990592740 hasAuthorship W2990592740A5043141680 @default.
• W2990592740 hasAuthorship W2990592740A5052188317 @default.
• W2990592740 hasAuthorship W2990592740A5054449436 @default.
• W2990592740 hasAuthorship W2990592740A5069618968 @default.
• W2990592740 hasAuthorship W2990592740A5070136704 @default.
• W2990592740 hasAuthorship W2990592740A5071628619 @default.
• W2990592740 hasAuthorship W2990592740A5072246651 @default.
• W2990592740 hasAuthorship W2990592740A5078660144 @default.
• W2990592740 hasAuthorship W2990592740A5083791593 @default.
• W2990592740 hasAuthorship W2990592740A5089632060 @default.
• W2990592740 hasBestOaLocation W29905927401 @default.
• W2990592740 hasConcept C112930515 @default.
• W2990592740 hasConcept C118552586 @default.
• W2990592740 hasConcept C126322002 @default.
• W2990592740 hasConcept C139719470 @default.
• W2990592740 hasConcept C142724271 @default.
• W2990592740 hasConcept C159110408 @default.
• W2990592740 hasConcept C162324750 @default.
• W2990592740 hasConcept C168563851 @default.
• W2990592740 hasConcept C1862650 @default.
• W2990592740 hasConcept C204787440 @default.
• W2990592740 hasConcept C27081682 @default.
• W2990592740 hasConcept C2776867660 @default.
• W2990592740 hasConcept C2777669559 @default.
• W2990592740 hasConcept C2779177272 @default.
• W2990592740 hasConcept C2779951463 @default.
• W2990592740 hasConcept C3019080777 @default.
• W2990592740 hasConcept C44249647 @default.
• W2990592740 hasConcept C535046627 @default.
• W2990592740 hasConcept C558461103 @default.
• W2990592740 hasConcept C64332521 @default.
• W2990592740 hasConcept C71924100 @default.
• W2990592740 hasConceptScore W2990592740C112930515 @default.
• W2990592740 hasConceptScore W2990592740C118552586 @default.
• W2990592740 hasConceptScore W2990592740C126322002 @default.
• W2990592740 hasConceptScore W2990592740C139719470 @default.
• W2990592740 hasConceptScore W2990592740C142724271 @default.
• W2990592740 hasConceptScore W2990592740C159110408 @default.
• W2990592740 hasConceptScore W2990592740C162324750 @default.
• W2990592740 hasConceptScore W2990592740C168563851 @default.

• next